<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02382341</url>
  </required_header>
  <id_info>
    <org_study_id>15000946</org_study_id>
    <nct_id>NCT02382341</nct_id>
  </id_info>
  <brief_title>BIOSURE™ HEALICOIL™ PK Bone In-growth Study</brief_title>
  <official_title>A Radiographic Study of Patients Treated With the BIOSURE™ HEALICOIL™ PK Interference Screw for ACL Repair With Soft Tissue Fixation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to document the bone in-growth into the BIOSURE™ HEALICOIL PK screw as&#xD;
      measured by CT scans. Patients' improvement in pain and function will also be followed&#xD;
      through various outcome measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the current study is to assess bone in-growth in the BIOSURE™&#xD;
      HEALICOIL™ Interference screw in the tibial tunnel of patients undergoing ACL reconstruction&#xD;
      with soft tissue grafts; tunnel widening and change in IKDC knee and subjective scores will&#xD;
      also be documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2014</start_date>
  <completion_date type="Actual">January 4, 2017</completion_date>
  <primary_completion_date type="Actual">January 4, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone In-growth measured by CT scans</measure>
    <time_frame>1 year</time_frame>
    <description>Bone In-growth measured by CT scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone In-growth measured by CT scans</measure>
    <time_frame>6 months</time_frame>
    <description>Bone In-growth measured by CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in IKDC Knee Examination scoring from baseline to 1 year post-operatively</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the IKDC Subjective Knee Evaluation scoring from baseline to 1 year post-operatively</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in IKDC Knee Examination scoring from baseline to 2 years post-operatively</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the IKDC Subjective Knee Evaluation scoring from baseline to 2 years post-operatively</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Deficiency of Anterior Cruciate Ligament</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>BIOSURE™ HEALICOIL™ PK Interference Screw</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOSURE™ HEALICOIL™ PK Interference Screw</intervention_name>
    <description>Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw</description>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing ACL reconstruction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ACL tear requiring surgical reconstruction with semitendinosus/gracilis graft.&#xD;
&#xD;
          -  Willing and able to give voluntary informed consent to participate in this study&#xD;
&#xD;
          -  Willing and able, in the opinion of the investigator, to cooperate with study&#xD;
             procedures and willing to return to study site for all post-operative study visits.&#xD;
&#xD;
          -  Subject is between 18 and 50 years at the time of surgery&#xD;
&#xD;
          -  ASA group 0-2 (limited medical illness).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revision ACL reconstruction&#xD;
&#xD;
          -  Cartilage injury (IKDC Grade IV lesion&gt; 2 cm2)&#xD;
&#xD;
          -  Current malignant disease&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Osteonecrosis or Avascular Necrosis&#xD;
&#xD;
          -  Ankylosing spondylitis&#xD;
&#xD;
          -  Subject is Obese; BMI &gt; 35&#xD;
&#xD;
          -  Subject is pregnant or plans to become pregnant during the study&#xD;
&#xD;
          -  Subject has received medical treatment within 6 weeks of enrollment with any of the&#xD;
             following:&#xD;
&#xD;
        Glucocorticoids Growth hormone&#xD;
&#xD;
          -  Participating in another investigational trial or on-going study that would interfere&#xD;
             with the assessment of the primary and secondary outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Lind, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACL</keyword>
  <keyword>BIOSURE</keyword>
  <keyword>HEALICOIL</keyword>
  <keyword>PEEK</keyword>
  <keyword>In-Growth</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

